DOCSLIB.ORG

Roger M. Katz, M.D. 11500W.Olympicblvd.,Suite630 Phone:(310)393-1550 Losangeles,CA90064 Fax:(310)478-3601

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Roger M. Katz, M.D. 11500W.Olympicblvd.,Suite630 Phone:(310)393-1550 Losangeles,CA90064 Fax:(310)478-3601 Roger M. Katz, M.D. 11500W.OlympicBlvd.,Suite630 Phone:(310)393-1550 LosAngeles,CA90064 Fax:(310)478-3601 PERSONAL Date of Birth: February 23, 1938 Place of Birth: Menominee, Michigan / Marinette, Wisconsin EDUCATION 1956 Marinette High School Marinette, WI 1956 - 1960 Bachelors of Science, University of Wisconsin Madison, WI 1960 - 1961 Masters Program, University of Louisville Louisville, KY 1961 - 1965 Doctor of Medicine, University of Louisville Medical School Louisville, KY 1965 - 1967 Michael Reese Medical Center - Internship / Residency: Pediatrics Chicago, IL 1967 - 1968 David Geffen School of Medicine at UCLA - Chief Resident: Los Angeles, CA Department of Pediatrics 1968 - 1970 Harbor/UCLA General Hospital - Allergy/Immunology Fellowship Los Angeles, CA 1969 - 1970 UCLA School of Public Health - Masters Program Public Health Los Angeles, CA 1969 - 1970 UCLA School of Public Health - Management Development Program Los Angeles, CA for Physicians 1996 University of Southern California - School of Business Administration Los Angeles, CA BOARD CERTIFICATION 1970 Pediatrics Certificate No. 13810 1970 Sub Board of Pediatric Allergy Certificate No. 295 1972 Allergy / Immunology Certificate No. 201 1977 Allergy / Immunology Re-Certified 1980 Pediatrics Re-Certified 1980 Pediatrics Sub Board Allergy Re-Certified HONORS Sep 1967 - Jan 1968 Chief Resident, Pediatrics David Geffen School of Medicine at UCLA 1969 Travel Grant - American Academy of Allergy, 25th Annual Meeting, Bal Harbor, FL 1970 Manuscript Award: Clemens Von Perquet, "Status of Exercise-Induced Bronchospasm" Congress of College of Allergists 1994 - 2014 Best Doctors in America 1996 - 2011 Best Doctors in America, Pacific Region 1974 - 2011 Who's Who In The Golden State 1996 - 2008 Who's Who In Medicine & Healthcare 2008 - 2014 Southern California Super Doctors - by Los Angeles Magazine Nov 18, 2008 Physician of the Year Award by Allergy Asthma Foundation of America May 28, 2014 Best Doctors in Southern California by Newsweek Magazine Oct 20, 2014 Top Allergist/Immunologist by the International Association of Healthcare Professionals PROFESSIONAL POSITIONS 1970 - 1972 Chief: Allergy/Immunology Service Houston, TX Fourth and Fifth Armies, Chief of Service Brooke General hospital, U.S. Army, Fort Sam 1970 - 1972 Clinical Assistant Professor Pediatrics San Antonio, TX University of Texas Medical School 1970 - 1972 Medical/Dental/Clinical Staff Consultant San Antonio, TX Department of Pediatrics Bexar County Hospital District 1971 - Present Consultant in Allergy to Commandant Houston, TX U.S. Army Medical Field Service School Brooke Army Medical Center, Fort Sam Page 1 of 11 David Geffen School of Medicine at UCLA Los Angeles, CA 1972 - 1976 Assistant Clinical Professor Pediatrics 1976 - 1980 Clinical Associate Professor Pediatrics 1977 - 1980 Clinical Faculty Committee 1980 - Present Clinical Professor Pediatrics 1973 - Present Consultant in Allergy News 1973 - 1980 Medical Consultant Tujunga, CA Sunair Asthmatic Home 1973 - Present Consultant to National Asthma Center Denver, CO Harbor General Hospital Torrance, CA 1975 - 1978 Director Juvenile Rheumatoid Arthritis Clinic 1976 - 1978 Co-director, Pediatric Immunology Clinic 1979 - 1988 Cedar Sinai Medical Center Los Angeles, CA Co-director Allergy / Immunology Clinic 1985 - Present California Board of Medical Quality Assurance Expert Medical Consultant 1986 - 1990 Harvard RBRVS Program: Chairman, Allergy / Immunology 1988 - 1990 Committee of Physicians and Payment Review Representative of Joint Council of Allergy, Asthma and Immunology PRESENT HOSPITAL AFFILIATIONS Current UCLA Santa Monica Hospital - Courtesy Staff Santa Monica,CA LICENSURE California Medical License: C29028 DEA: AK 509-4103 CCS: 15656 UCLA: 002234 UPIN: A33814 NPI: 1083721344 PROFESSIONAL SOCIETIES AND COMMITTEES 1971 - Present Fellow - American Academy of Pediatrics 1973 - Present Fellow - American Academy of Allergy and Immunology 1973 - Present Fellow - American College Allergy Asthma and Immunology 1978 - Present Fellow - American College of Chest Physicians 1978 - 1996 American College of Sports Medicine 1973 - Present Founding Fellow - American Association of Certified Allergists 1972 - 1974 Director of Los Angeles Chapter - American Lung Association 1974 - 1993 Director of Asthma Camp - Asthma and Allergy Foundation of America 1974 - 1994 Director of Los Angeles Chapter - Asthma and Allergy Foundation of America 1979 - 1995 Air Quality Advisory Committee - California State Department of Health Services 1972 - Present Los Angeles Pediatric Society 1972 - Present Member - Los Angeles County Medical Association 1977 - 1980 Executive Committee - Allergy Section - Los Angeles County Medical Association 1972 - Present Member - California Medical Association 1977 - 1980 Executive Committee - Allergy Section - California Medical Association 1979 President - Allergy Section - California Medical Association 1975 Secretary Treasurer - Los Angeles Society of Allergy and Clinical Immunology 1976 Vice President - Los Angeles Society of Allergy and Clinical Immunology 1977 President - Los Angeles Society of Allergy and Clinical Immunology 1976 - 1994 Western Society for Pediatric Research 1989 - 1992 Board of Regents - Member - American College of Allergy, Asthma & Immunology 1979 - 1989 Board of Directors - Joint Council of Allergy, Asthma, Immunology 1984 - 1986 President Elect - Joint Council of Allergy, Asthma, Immunology 1986 - 1990 President Joint Council of Allergy, Asthma, Immunology Page 2 of 11 PRIVATE PRACTICE OF MEDICINE - ALLERGY / IMMUNOLOGY / ASTHMA 1973 - 1983 Westchester, CA 1983 - 1994 Brentwood, CA 1994 - 1999 Westwood, CA 1999 - 2007 Santa Monica, CA 2007 - Present West Los Angeles, CA MEDICAL LEGAL CONSULTANT - Defense and Plaintiff 1990 - Present Medical Reviews / Examinations Medical review for vaccination reactions Expert Witness Depositions Court Appearances PUBLICATIONS Published papers No. 93 Published chapters No. 17 Published monographs No. 5 Published reviews No. 8 Letters to editor’s No. 7 Presentations to professional meetings No. 82 General public articles No. 50 Movies No. 2 CURRENT RESEARCH (Clinical) Allergy / Asthma Persistent, Moderate-Severe Asthma-Omalizumab (Novartis) [PPD] in Children 2005 - Present Persistent, Moderate-Severe Asthma-Omalizumab (Genetec) [Covance] Adults 2004 - Present COMPLETED RESEARCH (Clinical) Allergy/Asthma: ECP lab ananalysis in asthma (Hycor) 1996 - 1997 Albuterol via nebulizer in children/infants (Dey)[[RRI LLC] 1997 - 1998 Leukotriene inhibitors and ICS in childhood asthma AKNA 1998 - 2005 Levalbuterol v R albuterol v placebo children (Sepacor) [PPD] 1999 - 2000 Serevent vs. placebo (SMART STUDY) in adults [PARAGON-KENDLE] 2001 - 2002 Fluticasone discus vs. Montelucast in children 6-12 yrs [PARAGON] 2001 - 2002 Infectious Bacterial Sinusitis Adult, Abbott [The Phoenix] 2001 - 2002 Infectious Bacterial Sinusitis Adult, (Aventis TREAT) [PPD] 2001 - 2002 Fluticasone/salmeterol in children 4-11 yrs, GSK [PRA] 2003 - 2004 Symbicort, moderate severe asthma children 6-15 yrs(A-Z)[PPD] 2004 - 2006 Excels, Omalizumab LT study adults (Genentec-PPD) 2004 - Present Omalizumab in mod-severe asthma children 6-11 yrs (Novartis) 2005 - 2008 Asmanex dose ranging in adults (Sch-plgh, Covance) 2007 - 2012 Asthma / Food Allergies w/ Omalizumab 2009 - Present CURRENT MEDICAL INTERESTS Medical / Legal Reviews Business Management Nasacort Nasal Spray for Allergic Rhinitis for Children PAPERS PUBLISHED AND IN PRESS: 1. Katz RM. Quinaldine as an anesthetic on siredon mexicanum. Kentucky Academy of Science; 3:71-77. 2. Gyepes MT, Desilets DT, Gray RK, Katz RM. Epinephrine assisted renal venography in renal vein thrombosis. Radiology. 1969; 93:793-97. 3. Katz RM. Cough syncope in children with asthma. J Pediatric. 1970; 77:48-51. Page 3 of 11 4. Bluestone R, Goldberg L, Calabro JJ, Katz RM, Marcheshano J. Serological survey of 200 JRA patients. J Pediatric. 1970; 77:98-102. 5. Katz RM. Inappropriate post exercise hyperventilation. Ann Int Med. 1970; 73:138. 6. Calabro JJ, Katz RM, Marcheshano J. Pruritus in juvenile rheumatoid arthritis. Pediatrics.1970; 46:322-23. 7. Kaufman D, Katz RM, McIntosh R. Secretory IgE related to urinary tract infection. Br Med J 1970; 4:463-65. 8. Katz RM, Liebman W. Creatin phosphokinase activity in central nervous system disorders and infections. Amer J Dis Child. 1970; 120:543-46. 9. Katz RM, Whipp BJ, Heimlich EM, Wasserman DK. Exercise-induced Bronchospasm, ventilation and blood gases in asthmatic children. J Allergy. 1971; 47:148-58. 10. Katz RM. Exercise-induced Bronchospasm in asthmatics. Concepts Int Med. 1971; 4:421-27. 11. Katz RM, Liebman W. Creatin phosphokinase activity in cerebrospinal fluids. Amer J Dis Child.1971; 122:85-6. 12. Moore AL, Katz RM, MacIntosh R, Smith FG, Michael AF, Vernier RL. Unilateral renal vein thrombosis and the nephritic syndrome. Pediatrics. 1973; 50:568-608. 13. Katz RM, Kniker WT. Infantile hypersensitivity pneumonia as a reaction to organic antigens. N Engl J Med. 1973; 288:233-37. 14. Greenberg J, Smith TL, Katz RM. Verrucae vulgaris rejection: A preliminary study of contact dermatitis and cellular immunity response. Arch Dermat. 1973; 107:580-82. 15. Munster AM, Eurenius K, Katz RM, et al. Cell mediated immunity after thermal injury. Ann Surg. 1973; 177:139-43. 16. Rachelefsky GS, Terasaki PI, Katz RM, Stiehm ER. Increased prevalence of W27 in juvenile rheumatoid arthritis. N Engle J Med. 1973; 290:892-94. 17. Katz RM, Lieberman J,
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • 1532 Corticosteroids
    1532 Corticosteroids olone; Ultraderm; Malaysia: Synalar†; Mex.: Cortifung-S; Cortilona; Gr.: Lidex; Ital.: Flu-21†; Topsyn; Mex.: Topsyn; Norw.: Metosyn; Pharmacopoeias. In Br. Cremisona; Farmacorti; Flumicin; Fluomex; Fusalar; Lonason; Synalar; Philipp.: Lidemol; Lidex; Singapore: Lidex†; Spain: Klariderm†; Novoter; BP 2008 (Fluocortolone Hexanoate). A white or creamy-white, Norw.: Synalar; NZ: Synalar; Philipp.: Aplosyn; Cynozet; Synalar; Syntop- Switz.: To p s y m ; To p s y m i n ; UK: Metosyn; USA: Lidex; Vanos. ic; Pol.: Flucinar; Port.: Oto-Synalar N; Synalar; Rus.: Flucinar (Флуцинар); odourless or almost odourless, crystalline powder. It exhibits pol- Multi-ingredient: Austria: Topsym polyvalent; Ger.: Jelliproct; Topsym ymorphism. Practically insoluble in water and in ether; very Sinaflan (Синафлан); S.Afr.: Cortoderm; Fluoderm; Synalar; Singapore: polyvalent; Hung.: Vipsogal†; Israel: Comagis; Mex.: Topsyn-Y; Philipp.: Flunolone-V; Spain: Co Fluocin Fuerte; Cortiespec; Fluocid Forte; Fluoder- Lidex NGN; Spain: Novoter Gentamicina; Switz.: Mycolog N; Topsym slightly soluble in alcohol and in methyl alcohol; slightly soluble mo Fuerte; Flusolgen; Gelidina; Intradermo Corticosteroi†; Synalar; Synalar polyvalent; UK: Vipsogal. in acetone and in dioxan; sparingly soluble in chloroform. Pro- Rectal Simple; Swed.: Synalar; Switz.: Synalar; Thai.: Cervicum; Flu- ciderm†; Flunolone-V; Fulone; Supralan; Synalar; UK: Synalar; USA: Capex; tect from light. Derma-Smoothe/FS; DermOtic; Fluonid; Flurosyn†; Retisert; Synalar; Syn- emol; Venez.: Bratofil; Fluquinol Simple†; Neo-Synalar; Neoflu†. Fluocortin Butyl (BAN, USAN, rINNM) ⊗ Fluocortolone Pivalate (BANM, rINNM) ⊗ Multi-ingredient: Arg.: Adop-Tar†; Tri-Luma; Austria: Myco-Synalar; Procto-Synalar; Synalar N; Belg.: Procto-Synalar; Synalar Bi-Otic; Braz.: Butil éster de la fluocortina; Butylis Fluocortinas; Fluocortine Fluocortolone, pivalate de; Fluocortolone Trimethylacetate; Dermobel†; Dermoxin; Elotin; Fluo-Vaso; Neocinolon; Otauril†; Otocort†; Butyle; SH-K-203.
    [Show full text]
  • SUPPLEMENTARY APPENDIX 4: Search Strategies Syntax Guide For
    SUPPLEMENTARY APPENDIX 4: Search Strategies Pubmed, Embase Perioperative Management - PubMed Search Strategy – March 6, 2016 Syntax Guide for PubMed [MH] = Medical Subject Heading, also [TW] = Includes all words and numbers in known as MeSH the title, abstract, other abstract, MeSH terms, MeSH Subheadings, Publication Types, Substance Names, Personal Name as Subject, Corporate Author, Secondary Source, Comment/Correction Notes, and Other Terms - typically non-MeSH subject terms (keywords)…assigned by an organization other than NLM [SH] = a Medical Subject Heading [TIAB] = Includes words in the title and subheading, e.g. drug therapy abstracts [MH:NOEXP] = a command to retrieve the results of the Medical Subject Heading specified, but not narrower Medical Subject Heading terms Boolean Operators OR = retrieves results that include at least AND = retrieves results that include all the one of the search terms search terms NOT = excludes the retrieval of terms from the search Perioperative Management PubMed Search Strategy – March 6, 2016 Search Query #1 ((((ARTHROPLASTY, REPLACEMENT, HIP[MH] OR HIP PROSTHES*[TW] OR HIP REPLACEMENT*[TIAB] OR HIP ARTHROPLAST*[TIAB] OR HIP TOTAL REPLACEMENT*[TIAB] OR FEMORAL HEAD PROSTHES*[TIAB]) OR (ARTHROPLASTY, REPLACEMENT, KNEE[MH] OR KNEE PROSTHES*[TW] OR KNEE REPLACEMENT*[TW] OR KNEE ARTHROPLAST*[TW] OR KNEE TOTAL REPLACEMENT*[TIAB]) OR (ARTHROPLAST*[TW] AND (HIP[TIAB] OR HIPS[TIAB] OR KNEE*[TIAB])) AND (("1980/01/01"[PDAT] : "2016/03/06"[PDAT]) AND ENGLISH[LANG])) NOT (((("ADOLESCENT"[MESH]) OR "CHILD"[MESH])
    [Show full text]
  • Contact Dermatitis to Medications and Skin Products
    Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
    [Show full text]
  • Basic Skin Care and Topical Therapies for Atopic Dermatitis
    REVIEWS Basic Skin Care and Topical Therapies for Atopic Dermatitis: Essential Approaches and Beyond Sala-Cunill A1*, Lazaro M2*, Herráez L3, Quiñones MD4, Moro-Moro M5, Sanchez I6, On behalf of the Skin Allergy Committee of Spanish Society of Allergy and Clinical Immunology (SEAIC) 1Allergy Section, Internal Medicine Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain 2Allergy Department, Hospital Universitario de Salamanca, Alergoasma, Salamanca, Spain 3Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain 4Allergy Section, Hospital Monte Naranco, Oviedo, Spain 5Allergy Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain 6Clínica Dermatología y Alergia, Badajoz, Spain *Both authors contributed equally to the manuscript J Investig Allergol Clin Immunol 2018; Vol. 28(6): 379-391 doi: 10.18176/jiaci.0293 Abstract Atopic dermatitis (AD) is a recurrent and chronic skin disease characterized by dysfunction of the epithelial barrier, skin inflammation, and immune dysregulation, with changes in the skin microbiota and colonization by Staphylococcus aureus being common. For this reason, the therapeutic approach to AD is complex and should be directed at restoring skin barrier function, reducing dehydration, maintaining acidic pH, and avoiding superinfection and exposure to possible allergens. There is no curative treatment for AD. However, a series of measures are recommended to alleviate the disease and enable patients to improve their quality of life. These include adequate skin hydration and restoration of the skin barrier with the use of emollients, antibacterial measures, specific approaches to reduce pruritus and scratching, wet wrap applications, avoidance of typical AD triggers, and topical anti-inflammatory drugs. Anti-inflammatory treatment is generally recommended during acute flares or, more recently, for preventive management.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al
    US007544192B2 (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton et al. (45) Date of Patent: Jun. 9, 2009 (54) SINUS DELIVERY OF SUSTAINED RELEASE 5,443,498 A 8, 1995 Fontaine THERAPEUTICS 5,512,055 A 4/1996 Domb et al. 5,664,567 A 9, 1997 Linder (75) Inventors: Donald J. Eaton, Woodside, CA (US); 5,693,065. A 12/1997 Rains, III Mary L. Moran, Woodside, CA (US); 5,792,100 A 8/1998 Shantha Rodney Brenneman, San Juan Capistrano, CA (US) (73) Assignee: Sinexus, Inc., Palo Alto, CA (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 992 days. WO WOO1/02024 1, 2001 (21) Appl. No.: 10/800,162 (22) Filed: Mar 12, 2004 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2005/OO437O6A1 Feb. 24, 2005 Hosemann, W. et al. (Mar. 2003, e-pub. Oct. 10, 2002). “Innovative s Frontal Sinus Stent Acting as a Local Drug-Releasing System.' Eur: Related U.S. Application Data Arch. Otorhinolarynolo. 260:131-134. (60) Provisional application No. 60/454,918, filed on Mar. (Continued) 14, 2003. Primary Examiner Kevin C Sirmons (51) Int. Cl Assistant Examiner Catherine NWitczak A. iM sI/00 (2006.01) (74) Attorney, Agent, or Firm Morrison & Foerster LLP (52) U.S. Cl. ........................ 604/506; 604/510; 604/514 (57) ABSTRACT (58) Field of Classification Search .............. 604/93.01, 604/891.1. 890.1, 57, 59-64, 510, 514,506; S lication file f 606/196 The invention provides biodegradable implants for treating ee application file for complete search history.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Intranasal Steroids and the Myth of Mucosal Atrophy: a Systematic Review of Original Histological Assessments
    Intranasal steroids and the myth of mucosal atrophy: A systematic review of original histological assessments Misha M. Verkerk, M.B.B.S.,1 Daman Bhatia, M.B.B.S.,2 Janet Rimmer, F.R.A.C.P.,3 Peter Earls, F.R.C.P.A.,4 Raymond Sacks, M.D.,5 and Richard J. Harvey, M.D.6 ABSTRACT Background: Intranasal corticosteroids (INCSs) are well established in the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis. Although reversible atrophy of keratinized skin is seen with corticosteroids, the respiratory mucosa is histologically very different and but concerns remain among patients and some health-care professionals over local side effects on nasal respiratory mucosa. A systematic review and meta-analysis were performed of the available evidence for nasal mucosal atrophy as an adverse effect of INCSs in patients with sinonasal disease. Methods: A systematic search of Embase (1974-) and Medline (1946-) databases to September 27, 2013 was performed. Inclusion criteria selected any study where the histopathology of nasal mucosa was assessed in patients with sinonasal disease using intranasally administered corticosteroids with or without a control group. Results: Twenty-three hundred sixty-four publications were retrieved with a subsequent full text review of 149 publications for 34 articles that met the selection criteria. These articles included 11 randomized controlled trials, 5 cohorts, and 20 case series. Duration of treatment varied from 5 days to 5.5 years. “Mucosal atrophy” as an outcome was reported in 17 studies. The definition of “mucosal atrophy” was highly variable with a definition given in only 10 studies.
    [Show full text]
  • A Systematic Review of the Safety of Topical Therapies for Atopic Dermatitis J
    REVIEW ARTICLE DOI 10.1111/j.1365-2133.2006.07538.x A systematic review of the safety of topical therapies for atopic dermatitis J. Callen, S. Chamlin,* L.F. Eichenfield, C. Ellis,à M. Girardi,§ M. Goldfarb,à J. Hanifin,– P. Lee, D. Margolis,** A.S. Paller,* D. Piacquadio, W. Peterson, K. Kaulback,àà M. Fennerty– and B.U. Wintroub§§ Department of Dermatology, University of Louisville, Louisville, KY, U.S.A. *Department of Dermatology, Northwestern University’s Feinberg School of Medicine, Chicago, IL, U.S.A. Department of Dermatology, University of California San Diego, San Diego, CA, U.S.A. àDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, U.S.A. §Department of Dermatology, Yale University School of Medicine, New Haven, CT, U.S.A. –Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A. **Departments of Dermatology and Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA, U.S.A. Department of Gastroenterology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, U.S.A. ààMedical Advisory Secretariat, Ministry of Health and Long Term Care, Toronto, ON, Canada §§Department of Dermatology, University of California San Francisco, 1701 Division Street, Room 338, San Francisco, CA 94143-0316, U.S.A. Summary Correspondence Background The safety of topical therapies for atopic dermatitis (AD), a common Bruce U. Wintroub. and morbid disease, has recently been the focus of increased scrutiny, adding E-mail: [email protected] confusion as how best to manage these patients. Objectives The objective of these systematic reviews was to determine the safety of Accepted for publication 9 June 2006 topical therapies for AD.
    [Show full text]
  • BDS: CALUX Bioassays
    Water safety assessment by Bioassays Cell based toxicity screening by a panel of CALUX bioassays Dr. Peter A. Behnisch Director BioDetection Systems, Amsterdam, The Netherlands Email: [email protected] ©BDS all rights reserved Who we are BioDetection Systems B.V. (“BDS”) is a Dutch company and ISO 17025 accredited service laboratory providing biological detection systems, such as the innovative CALUX bioassays for the determination of ultra low levels of a variety of highly potent materials. Mission To provide innovative bioassays and implement their use to the highest international standards. Partner in many international projects related to water: • EC FP6 “TECHNEAU ” • Rhine Monitoring Project (RIWA) • EC FP7 ChemScreen for REACH/3Rs • Dutch Projects, z. Bsp. LEOS, ZORG, Genes4Water ©BDS all2 rights reserved CALUX ® Principles Add substrate (luciferin) LightLight measurement Toxicity via luminometer Luciferase Dioxin Proteins Endocrine Enzymes Disrupting Chemicals Transport protein Dioxin receptor Dioxin Hormonebinding Binding Hsp Dioxin Responsive Transcription Element (CRE) Nucleus Cytosol ©BDS all rights reserved 1 Panel of CALUX ® biotests • Endocrine ER AR PR KappaB nrf2 cytox p53 TR GR RAR • Acute DR KappaB p21 cytox PPAR • Repro ER AR PR TR GR RAR • Immuno DR KappaB nrf2 cytox PPAR p53 ER AR PR p21 GR RAR DR KappaB nrf2 cytox PPAR • Development ER AR PR TR GR RAR ER AR TR DR KappaB GR RAR DR nrf2 cytox KappaB PPAR p53 cytox PPAR • Muta/carcinogen p21 ©BDS all rights reserved BDS’s CALUX and typical applications (1) • DR-CALUX (dioxins, furans, PCBs, POPs, PAKs, Ah receptor ligands) • ERα-CALUX (natural, synthetic and plant-like estrogens, pseudo-estrogens, DES, endocrine disrupters, tamoxifen and other anti-estrogens) • ERβ-CALUX (like ERα-CALUX, but more for plant-like estrogens ) • AR-CALUX (androgens, anabolic steroids, pseudo- androgens, antibiotic growth promoters, nandrolone, flutamide e.a.
    [Show full text]
  • United States Patent (10) Patent No.: US 9.447,027 B2 Milan Et Al
    US009447027B2 (12) United States Patent (10) Patent No.: US 9.447,027 B2 Milan et al. (45) Date of Patent: Sep. 20, 2016 (54) TREATING LONG QT SYNDROME 2004/O1972.71 A1* 10, 2004 Kunka et al. ................... 424/45 2006/0173058 A1* 8, 2006 Brown .................... CO7C 65/05 514,381 (75) Inventors: Es l, St. MS 2006/0173508 A1* 8, 2006 Stone ................. A61N 1,36085 aVId S. Peal, SomerV11 le. (US) 607/40 (73) Assignee: The General Hospital Corporation, FOREIGN PATENT DOCUMENTS Boston, MA (US) JP 11209328 A1 * 8, 1999 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 86 days. Nademanee, K. et al., Annals of the New York Academy of Sciences vol. 522, pp. 536-552, published 2006.* (21) Appl. No.: 13/822,264 Chouabe, C. et al., Molecular Pharmacology vol. 54 pp. 696-703, published 1998.* (22) PCT Filed: Oct. 20, 2011 Nishizawa, S., et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.e1-1167.e3, published Nov. 2009).* (86). PCT No.: PCT/US2011/057087 Nishizawa et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.el -1167.e3, published Nov. 2009).* S 371 (c)(1), Nishizawa et al (American Journal of Emergency Medicine vol. 27. (2), (4) Date: Jul. 22, 2013 pp. 1167.e1-1167.e3, published Nov. 2009).* Anderson et al., “Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism.” Circula (87) PCT Pub. No.: WO2012/054718 tion 113:365-373, 2006, 10 pages.
    [Show full text]
  • WO 2009/023943 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 26 February 2009 (26.02.2009) PCT WO 2009/023943 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61P 27/16 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (21) International Application Number: PCT/BR2008/000248 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, (22) International Filing Date: 18 August 2008 (18.08.2008) IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (25) Filing Language: English LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, (26) Publication Language: English RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, (30) Priority Data: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, PI 0703127-0 22 August 2007 (22.08.2007) BR ZW (71) Applicant (for all designated States except US): OURO FINO PARTICIPAς ό ES E EMPREENDIMENTOS (84) Designated States (unless otherwise indicated, for every LTDA [BR/BR]; Avenida Independencia, 3220 sala 04, kind of regional protection available): ARIPO (BW, GH, Alto da Boa Vista, Ribeirao Preto - Sp (BR). GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (72) Inventors; and European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, (75) Inventors/Applicants (for US only): MASSARI, Jardel FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, [BR/BR]; Av.
    [Show full text]